These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Autofluorescence endoscopy in surveillance of Barrett's esophagus: a multicenter randomized trial on diagnostic efficacy. Borovicka J; Fischer J; Neuweiler J; Netzer P; Gschossmann J; Ehmann T; Bauerfeind P; Dorta G; Zürcher U; Binek J; Meyenberger C Endoscopy; 2006 Sep; 38(9):867-72. PubMed ID: 16981102 [TBL] [Abstract][Full Text] [Related]
46. Screening strategies in gastroesophageal reflux disease: early identification of esophageal carcinoma. Shaheen NJ; Provenzale D Adv Intern Med; 2001; 47():137-57. PubMed ID: 11795073 [No Abstract] [Full Text] [Related]
47. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Katz D; Rothstein R; Schned A; Dunn J; Seaver K; Antonioli D Am J Gastroenterol; 1998 Apr; 93(4):536-41. PubMed ID: 9576444 [TBL] [Abstract][Full Text] [Related]
50. New developments in the endoscopic surveillance of Barrett's oesophagus. Bergman JJ; Tytgat GN Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i38-42. PubMed ID: 15711007 [TBL] [Abstract][Full Text] [Related]
51. Prediction of Barrett's esophagus: are we there yet? Gaddam S Dis Esophagus; 2018 Mar; 31(3):. PubMed ID: 29346553 [No Abstract] [Full Text] [Related]
52. Barrett's esophagus: a retrospective analysis of 13 years surveillance. Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769 [TBL] [Abstract][Full Text] [Related]
53. Understanding cancer incidence in Barrett's esophagus: light at the end of the tunnel. Corley DA J Natl Cancer Inst; 2011 Jul; 103(13):994-5. PubMed ID: 21680911 [No Abstract] [Full Text] [Related]
54. Critical reappraisal of current surveillance strategies for Barrett's esophagus: analysis of a large German Barrett's database. von Rahden BH; Stein HJ; Weber A; Vieth M; Stolte M; Rösch T; Schmid RM; Sarbia M; Meining A Dis Esophagus; 2008; 21(8):685-9. PubMed ID: 18847456 [TBL] [Abstract][Full Text] [Related]
56. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia. Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445 [TBL] [Abstract][Full Text] [Related]
57. [Topic Complex VI: Barrett esophagus]. Messmann H; Ell C; Fein M; Kiesslich R; Ortner M; Porschen R; Stolte M Z Gastroenterol; 2005 Feb; 43(2):184-90. PubMed ID: 15700212 [No Abstract] [Full Text] [Related]
58. [Screening for adenocarcinoma in Barrett's esophagus: yes or no, when and how?]. Sostres C; Lacarta P; Lanas A Gastroenterol Hepatol; 2013 Oct; 36(8):520-6. PubMed ID: 23453559 [TBL] [Abstract][Full Text] [Related]
59. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma. Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218 [TBL] [Abstract][Full Text] [Related]
60. [Diagnosis of gastroesophageal reflux and Barrett esophagus]. von Schrenck T Zentralbl Chir; 2000; 125(5):414-23. PubMed ID: 10929625 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]